Miromatrix Medical Inc. (MIRO)

Market Cap	92.95M
Revenue (ttm)	958,029
Net Income (ttm)	-27.41M
Shares Out	27.42M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	631,561
Open	3.380
Previous Close	3.390
Day's Range	3.380 - 3.390
52-Week Range	0.910 - 3.730
Beta	0.02
Analysts	Buy
Price Target	3.00 (-11.5%)
Earnings Date	Nov 14, 2023

About MIRO

Miromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 24, 2021
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRO
• Website: https://www.miromatrix.com

Financial Performance

In 2022, MIRO's revenue was $953,470, an increase of 2783.54% compared to the previous year's $33,066. Losses were -$29.96 million, 104.2% more than in 2021.

Analyst Summary

According to one analyst, the rating for MIRO stock is "Buy" and the 12-month stock price target is $3.0.

Price Target

$3.0

(-11.50% downside)

Analyst Consensus: Buy